Evidence map›Paper›PMID 21198543›Full record

ArticleBritish journal of pharmacology2011

Fenamates as TRP channel blockers: mefenamic acid selectively blocks TRPM3.

Chihab Klose, Isabelle Straub, Marc Riehle, Felicia Ranta, Dietmar Krautwurst, Susanne Ullrich, Wolfgang Meyerhof, Christian Harteneck

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 121 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. [Advances in the development of transient receptor potential melastatin 2 channel inhibitors].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  9. Astrocyte gap junctions and KFrontiers in cellular neuroscience · 2025
    Article
  10. Review
  11. Navigating the Controversies: Role of TRPM Channels in Pain States.International journal of molecular sciences · 2024
    Review
  12. Article
  13. TRPM2 Channels: A Potential Therapeutic Target in Melanoma?International journal of molecular sciences · 2023
    Review
  14. Hyperthermia and Serotonin: The Quest for a "Better Cyproheptadine".International journal of molecular sciences · 2022
    Review
  15. Ion Channels in Cancer: Orchestrators of Electrical Signaling and Cellular Crosstalk.Reviews of physiology, biochemistry and pharmacology · 2022
    Review
  16. Article
  17. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  18. Article
  19. TRPM3 in Brain (Patho)Physiology.Frontiers in cell and developmental biology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Chihab KloseDepartment of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Interfaculty Center of Pharmacogenomics and Pharmaceutical Research (ICePhA), Eberhard-Karls-University, Tübingen, Germany.
Isabelle Straub
Marc Riehle
Felicia Ranta
Dietmar Krautwurst
Susanne Ullrich
Wolfgang Meyerhof
Christian Harteneck
University of Tübingen · DEGerman Institute of Human Nutrition · DELeibniz-Institute for Food Systems Biology at the Technical University of Munich · DEZero to Three · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeFenamates are N-phenyl-substituted anthranilic acid derivatives clinically used as non-steroid anti-inflammatory drugs in pain treatment. Reports describing fenamates as tools to interfere with cellular volume regulation attracted our attention based on our interest in the role of the volume-modulated transient receptor potential (TRP) channels TRPM3 and TRPV4. EXPERIMENTAL APPROACH: Firstly, we measured the blocking potencies and selectivities of fenamates on TRPM3 and TRPV4 as well as TRPC6 and TRPM2 by Ca(2+) imaging in the heterologous HEK293 cell system. Secondly, we further investigated the effects of mefenamic acid on cytosolic Ca(2+) and on the membrane voltage in single HEK293 cells that exogenously express TRPM3. Thirdly, in insulin-secreting INS-1E cells, which endogenously express TRPM3, we validated the effect of mefenamic acid on cytosolic Ca(2+) and insulin secretion. KEY

resultsWe identified and characterized mefenamic acid as a selective and potent TRPM3 blocker, whereas other fenamate structures non-selectively blocked TRPM3, TRPV4, TRPC6 and TRPM2. CONCLUSIONS AND IMPLICATIONS: This study reveals that mefenamic acid selectively inhibits TRPM3-mediated calcium entry. This selectivity was further confirmed using insulin-secreting cells. K(ATP) channel-dependent increases in cytosolic Ca(2+) and insulin secretion were not blocked by mefenamic acid, but the selective stimulation of TRPM3-dependent Ca(2+) entry and insulin secretion induced by pregnenolone sulphate were inhibited. However, the physiological regulator of TRPM3 in insulin-secreting cells remains to be elucidated, as well as the conditions under which the inhibition of TRPM3 can impair pancreatic β-cell function. Our results strongly suggest mefenamic acid is the most selective fenamate to interfere with TRPM3 function.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalCalciumFenamatesHEK293 CellsHumansInsulinInsulin-Secreting CellsMefenamic AcidMiceTRPC Cation ChannelsTRPM Cation ChannelsTRPV Cation ChannelsAnti-Inflammatory Agents, Non-SteroidalCalciumFenamatesInsulinMefenamic AcidTRPC Cation ChannelsTRPM3 protein, humanTRPM Cation ChannelsTRPV4 protein, humanTRPV Cation Channels

Identifiers

PMID21198543
PMCPMC3081119
OpenAlexW1502101880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.